Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson’s disease

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Expert Opinion on Drug Metabolism & Toxicology

• Publication date

  2017-05-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/17425255.2017.1329418PMID 28537214
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial

  2017cited by this paper
• Use of monoamine oxidase inhibitors in chronic neurodegeneration

  2017cited by this paper
• Effects of Safinamide on Pain in Fluctuating Parkinson’s Disease Patients: A Post-Hoc Analysis

  2016cited by this paper
• Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease

  2016cited by this paper
• Advances in understanding genomic markers and pharmacogenetics of Parkinson’s disease

  2016cited by this paper
• Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson’s Disease: A Post-Hoc Analysis

  2015cited by this paper
• A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson’s disease patients

  2015cited by this paper
• Catechol-O-Methyltransferase Inhibitors in Parkinson’s Disease

  2015cited by this paper
• Safinamide: First Global Approval

  2015cited by this paper
• Meta-analysis of Placebo-controlled Clinical Trials of Safinamide and Entacapone as Add-on Therapy to Levodopa in the Treatment of Parkinson's Disease

  2015cited by this paper
• Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study)

  2015cited by this paper
• Two‐year, randomized, controlled study of safinamide as add‐on to levodopa in mid to late Parkinson's disease

  2014cited by this paper
• Mavoglurant as a treatment for Parkinson’s disease

  2014cited by this paper
• Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.

  2013cited by this paper
• AFQ056 in Parkinson patients with levodopa‐induced dyskinesia: 13‐week, randomized, dose‐finding study

  2013cited by this paper
• [Epidemiology of Parkinson's disease].

  2013cited by this paper
• Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor.

  2013cited by this paper
• Absolute Bioavailability and Effect of Food on the Disposition of Safinamide Immediate Release Tablets in Healthy Adult Subjects

  2013cited by this paper
• The PRIPS study: screening battery for subjects at risk for Parkinson's disease

  2013cited by this paper
• Switch from selegiline to rasagiline is beneficial in patients with Parkinson’s disease

  2013cited by this paper
• Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations

  2013cited by this paper
• Disposition and Metabolism of Safinamide, a Novel Drug for Parkinson's Disease, in Healthy Male Volunteers

  2013cited by this paper
• Rasagiline

  2012cited by this paper
• Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects

  2012cited by this paper
• Drug therapy in patients with Parkinson’s disease

  2012cited by this paper
• Impact of complications and comorbidities on treatment costs and health-related quality of life of patients with Parkinson's disease.

  2012cited by this paper
• Dopamine, Corticostriatal Connectivity, and Intertemporal Choice

  2012cited by this paper
• Amantadine

  2012cited by this paper
• The pharmacology of selegiline.

  2011cited by this paper
• Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers

  2011cited by this paper
• The Impact of COMT-inhibition on Gastrointestinal Levodopa Absorption in Patients with Parkinson's Disease:

  2010cited by this paper
• Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-O-methyltransferase rs4818c/g polymorphism.

  2009cited by this paper
• What do clinical trials tell us about treating patients?

  2009cited by this paper
• Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)

  2008cited by this paper
• There is no Parkinson disease.

  2008cited by this paper
• Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease.

  2007cited by this paper
• Tolcapone Improves Cognition and Cortical Information Processing in Normal Human Subjects

  2007cited by this paper
• Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease

  2006cited by this paper
• Levodopa, motor fluctuations and dyskinesia in Parkinson’s disease

  2006cited by this paper
• Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity.

  2004cited by this paper
• Diagnostic staging of Parkinson’s disease: conceptual aspects

  2004cited by this paper
• A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.

  2003cited by this paper
• A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease

  2003cited by this paper
• Pressor Response to Intravenous Tyramine in Healthy Subjects After Safinamide, a Novel Neuroprotectant With Selective, Reversible Monoamine Oxidase B Inhibition

  2003cited by this paper
• Assessment, pathophysiology and treatment of fatigue in multiple sclerosis

  2002cited by this paper
• Motor fluctuations and dyskinesia in Parkinson's disease.

  2001cited by this paper
• Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group.

  2000cited by this paper
• Levodopa in plasma correlates with body weight of parkinsonian patients.

  2000cited by this paper
• SELEDO: a 5‐y‐ear long‐term trial on the effect of selegiline in early parkinsonian patients treated with levodopa

  1999cited by this paper
• Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder.

  1999cited by this paper
• Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.

  1999cited by this paper
• Catechol-O-methyltransferase inhibitors in Parkinson's disease.

  1998cited by this paper
• Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.

  1998cited by this paper
• Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

  1998cited by this paper
• Preclinical evaluation of PNU-151774E as a novel anticonvulsant.

  1998cited by this paper
• Cognitive improvement during Tolcapone treatment in Parkinson's disease

  1997cited by this paper
• Epidemiology of Parkinson's disease.

  1997cited by this paper
• Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson’s disease

  1997cited by this paper
• Pharmacology of selegiline

  1996cited by this paper
• Tolcapone: a potential new antidepressant detected in a novel animal model of depression

  1994cited by this paper
• Treatment of Impaired Cerebral Function in Psychogeriatric Patients with Memantine - Results of a Phase II Double-Blind Study

  1988cited by this paper

• Investigation of small molecules disrupting dengue virus assembly by inhibiting capsid protein and blocking RNA encapsulation

  2024cites this paper
• The role of istradefylline in the Parkinson’s disease armamentarium

  2023cites this paper
• Application of a Quality by Design Approach to Develop a Simple, Fast, and Sensitive UPLC-MS/MS Method for Quantification of Safinamide, an Antiparkinson’s Drug, in Plasma

  2023cites this paper
• Establishment of a sensitive UPLC-MS/MS method to quantify safinamide in rat plasma

  2023cites this paper
• Safinamide Detection Based on Prussian Blue Analogue Modified Solid-contact Potentiometric Sensor

  2023cites this paper
• DoE-enhanced development and validation of eco-friendly RP-HPLC method for analysis of safinamide and its precursor impurity: QbD approach

  2023cites this paper
• Green spectrophotometric platforms for resolving overlapped spectral signals of recently approved antiparkinsonian drug (Safinamide) in presence of its synthetic precursor (4-Hydroxybenzaldehyde): Applying ecological appraisal and Comparative statistical studies

  2022cites this paper
• Versatile eco-friendly electrochemical sensor based on chromium-doped zinc oxide nanoparticles for determination of safinamide aided by green assessment criteria

  2022cites this paper
• Modulation of biopharmaceutical properties of drugs using sulfonate counterions: A critical analysis of FDA-approved pharmaceutical salts

  2021cites this paper
• Parkinson's pharmacological therapy

  2021cites this paper
• Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson’s disease

  2021cites this paper
• Questions in the Chemical Enzymology of MAO

  2021cites this paper
• "Ligand-Based Virtual Screening for the Inhibitors of Monoamine Oxidase B"

  2021cites this paper
• Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future

  2021cites this paper
• Safinamide in neurological disorders and beyond: evidence from preclinical and clinical studies.

  2020cites this paper
• Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson’s disease

  2020cites this paper
• A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice

  2020cites this paper
• Safinamide – a monoamine oxidase-B inhibitor and a glutamate modulator

  2020cites this paper
• Recent developments in pharmaceutical salts: FDA approvals from 2015 to 2019.

  2020cites this paper
• [Safinamide Mesilate (Equfina® TABLETS 50 mg): preclinical and clinical pharmacodynamics, efficacy, and safety].

  2020cites this paper
• Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice

  2020cites this paper
• Therapeutic Agents for Neurodegenerative Disorders

  2019cites this paper
• ABCB1: is there a role in the drug treatment of Parkinson’s disease?

  2018cites this paper
• Cellular phenotypes as inflammatory mediators in Parkinson's disease: Interventional targets and role of natural products.

  2018cites this paper
• Safinamide: a new hope for Parkinson's disease?

  2018cites this paper
• Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases

  2018cites this paper